1. 3112 Nintedanib in combination with cisplatin/gemcitabine as 1st-line therapy for advanced squamous non-small cell lung cancer. (September 2015) Authors: Forster, M.; Hackshaw, A.; Pas, T. De; Cobo, M.; Garrido, P.; Summers, Y.; Dingemans, A.M.; Flynn, M.; Von Wangenheim, U.; Temple, G.; Loembé, A.B.; Lee, S.M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S639 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 316 Phase I study of lurbinectedin (PM01183) in combination with cisplatin (C) with or without aprepitant (Ap) in patients (pts) with advanced solid tumors. (September 2015) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Coronado, C.; Juan, L.; Fernandez-Teruel, C.; Soto-Matos, A.; Stathis, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S60 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. (November 2018) Authors: Arkenau, H.-T.; Italiano, A.; Mak, G.; Toulmonde, M.; Baird, R.D.; Garcia-Corbacho, J.; Plummer, R.; Flynn, M.; Forster, M.; Wilson, R.H.; Tosi, D.; Adenis, A.; Donaldson, K.; Posner, J.; Kawabata, I.; Arimura, A.; Deva, S.; Spicer, J. Journal: European journal of cancer Issue: Volume 103(2018) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. KRAS: Reasons for optimism in lung cancer. (August 2018) Authors: Lindsay, C.R.; Jamal-Hanjani, M.; Forster, M.; Blackhall, F. Journal: European journal of cancer Issue: Volume 99(2018) Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. (December 2016) Authors: Schaefer, E.; Braiteh, F.; Forster, M.; Talbot, D.; Chandler, J.; Richards, D.; Andre, V.; Estrem, S.; Pitou, C.; Tiu, R.; Brail, L.; Nikolinakos, P. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors. (February 2017) Authors: Forster, M.; Sessa, C.; Von Moos, R.; Brown, N.; Metaxas, Y.; Griguolo, G.; Lardelli, P.; Iglesias, J.; Fernandez-Teruel, C.; Jandali, U.; Soto-Matos, S.M.; Stathis, A. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S134 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗